Back

Estimation of the target population of a selective cardiac myosin inhibitor for hypertrophic obstructive cardiomyopathy: Real-life data from the French REMY register.

22 May 2023 (14:00 - 14:45)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - hypertrophic cardiomyopathy 3 Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Mrs Tanya Muresan

European Hospital Georges Pompidou, Paris (France)

6 More presentations in this session

Presentation thumbnail
Patient-reported outcome measures in wild-type and variant cardiac transthyretin amyloidosis: the ITALY (impact of transthyretin amyloidosis on life quality) study
Doctor A. Aimo (Pisa, IT)
Abstract Slides
Presentation thumbnail
Echocardiography machine learning based to improve detection of transthyretin cardiac amyloidosis: the R3M algorithm
Doctor A. Fraix (Nancy, FR)
Abstract Slides
Presentation thumbnail
Hypertrophic cardiomyopathy in female patients is associated with symptomatic heart failure and worse functional and exercise capacity
Doctor Y. Wasserstrum (Ramat Gan, IL)
Abstract Slides
Presentation thumbnail
Relative apical longitudinal strain: a powerful tool to predict outcomes in transthyretin amyloid cardiomyopathy
Doctor M. Castro (Guimaraes, PT)
Abstract Slides
Presentation thumbnail
A novel myocardium functional echocardiographic parameter, left ventricular myocardial work, associates with sudden cardiac risk score in patients with hypertrophic cardiomyopathy
Doctor G. Racz (Stavanger, NO)
Abstract Slides

Access the full session

Session thumbnail
Myocardial disease - hypertrophic cardiomyopathy 3

The Event

Event poster

Heart Failure 2023

22 May 2023 14:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources